Skip to content
Open access

Fluoropyrimidine-associated gastrointestinal toxicity: pharmacovigilance reporting signals and in vitro evidence of epithelial injury, barrier impairment, and inflammatory responses

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 39 references
Medicine

TL;DR

Experimental evidence is provided that fluoropyrimidine exposure is associated with epithelial injury, impaired barrier function, and epithelial inflammatory responses, and the reporting signals do not estimate event frequency in treated populations or establish causality.

Abstract

Introduction Fluoropyrimidines, including 5-fluorouracil (5-FU), capecitabine, tegafur, and trifluridine, are widely used anticancer agents, but their gastrointestinal toxicities remain clinically important. This study characterized fluoropyrimidine-associated adverse-event reporting signals across multiple pharmacovigilance databases and described epithelial-cell responses that may provide experimental context for gastrointestinal toxicity. Methods Adverse-event reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS), Japanese Adverse Drug Event Report database (JADER), and Canada Vigilance Adverse Reaction Database (CVARD) were analyzed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM) approaches. Time to onset (TTO) analysis was limited to FAERS because complete onset information was unavailable in JADER and CVARD. GES-1 gastric epithelial cells and NCM460 colonic epithelial cells were used for acute and 7-day repeated-exposure injury experiments. Additional representative-treatment experiments assessed fluorescein isothiocyanate (FITC)-dextran permeability and relative supernatant interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels. Results Fluoropyrimidines showed gastrointestinal reporting signals with drug-specific reporting patterns. TTO analysis in FAERS showed an overall early-reporting pattern; the distribution of reports between days 181 and 360 was exploratory. In vitro, fluoropyrimidines reduced epithelial viability, increased lactate dehydrogenase (LDH) release and reactive oxygen species (ROS) accumulation and decreased the JC-1 red/green ratio. Epithelial injury was also observed under the 7-day repeated-exposure conditions. Quantitative real-time polymerase chain reaction (qPCR) showed lower TJP1, OCLN, and CDH1 transcript abundance and increased expression of selected epithelial inflammatory-response and extracellular-matrix-remodeling genes. In the functional assays, FITC-dextran permeability and relative supernatant IL-6 and TNF-α levels increased after 5-FU, capecitabine, and trifluridine exposure. Conclusion This study identifies pharmacovigilance reporting signals and provides experimental evidence that fluoropyrimidine exposure is associated with epithelial injury, impaired barrier function, and epithelial inflammatory responses. The reporting signals do not estimate event frequency in treated populations or establish causality and require confirmation in exposure-adjusted studies.

Read PDF

Similar papers

Open access Nov 2026

Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study

Real-world safety profiles of targeted therapies for colorectal cancer (CRC) remain incompletely characterized, particularly across different chemotherapy backbones. This study characterizes adverse event (AE) reporting patterns for bevacizumab (BVZ), cetuximab (C225), and panitumumab (VEC), used as monotherapy or in c...

You-Qiang Liu, Zhi-Han Li, Gang Li et al. · 0 citations
Open access Oct 2026

Multisystem toxicity signals of antibody–drug conjugates in solid tumors: A FAERS pharmacovigilance analysis, 2020–2025.

376 Background: Antibody-drug conjugates (ADCs) have transformed treatment of solid tumors; however, payload-driven toxicities may affect symptom burden, treatment continuity, and outcomes. Clinical trials are often underpowered to detect delayed or multisystem adverse events and may not reflect real-world popu...

Z. Sarfraz, Tanay Venkat Malla, Ayush Patel et al. · 0 citations
Open access Oct 2026

Mucosal, Ocular, and Pulmonary Adverse Events Reported with Datopotamab Deruxtecan: An Indication-Restricted Disproportionality Analysis of the FDA Adverse Event Reporting System

Background/Objectives: Datopotamab deruxtecan was approved in 2025 for hormone receptor-positive, HER2-negative metastatic breast cancer and for EGFR-mutated non-small cell lung cancer (NSCLC); its safety profile in routine use has not been described. We characterized adverse event reporting for the agent and asked whe...

Osman Bilge Kaya, B. Karabuğa, E. Aydemir et al. · 0 citations
Open access Nov 2026

Gastrointestinal safety signals of Janus kinase inhibitors: a real-world pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System.

BACKGROUND Janus kinase inhibitors (JAKis) are increasingly used in dermatology, yet their gastrointestinal safety profiles remain incompletely characterized in real-world practice. Although gastrointestinal adverse events (GIAEs) are generally mild, gastrointestinal perforation remains an important safety concern with...

Esra Kıratlı Nalbant, Banu İsmail Mendi · 0 citations
Open access Nov 2026

Neurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases

Neurological adverse events (NAEs) have been reported during immune checkpoint inhibitor (ICI) therapy, but their reporting spectrum and onset patterns across drugs and pharmacovigilance databases remain incompletely characterized. We conducted a pharmacovigilance study of seven ICIs using the FDA Adverse Ev...

Hui-Ling Luo, Xian-Long Xie, Shi-Ran Qin et al. · 0 citations
Open access Oct 2026

Hepatic adverse-event reporting after CAR T-cell therapy: a pharmacovigilance analysis of FAERS and Canada Vigilance

Hepatic adverse events after chimeric antigen receptor (CAR) T-cell therapy may reflect cytokine release syndrome, immune effector cell-associated haemophagocytic syndrome/haemophagocytic syndrome/haemophagocytic lymphohistiocytosis, or immune-mediated drug-induced liver injury, which warrants prospective clinical eval...

Saikat Mandal, Manideepa Maji, A. Dhali et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.